Skip to main content
Premium Trial:

Request an Annual Quote

Ipsum Diagnostics Coronavirus Test Gets FDA Emergency Use Authorization

NEW YORK — The US Food and Drug Administration on Wednesday granted Emergency Use Authorization to Ipsum Diagnostics for the company's RT-PCR-based SARS-CoV-2 test.

According to the FDA, the test, called COV-19 IDx, is designed to detect a region in the SARS-CoV-2 nucleocapsid gene, as well as human RNase P as a control, in nasopharyngeal and oropharyngeal swab specimens. Nucleic acid extraction is performed using Thermo Fisher Scientific's KingFisher Flex nucleic acid extraction system and the Omega Bio-Tek Mag-Bind Viral DNA/RNA 96 kit, and the test runs on Thermo Fisher's Applied Biosystems QuantStudio 12 K Flex instrument.

Emergency use of the test is limited to Ipsum and other authorized laboratories, the FDA noted.

Atlanta-based Ipsum is offering COV-19 IDx supplies and kits via a physician portal on its website

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.